Fabino Enterprises Ltd vs Senores Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Fabino Enterprises Ltd is ₹ 20.31 as of 27 Apr 15:30 . The P/E Ratio of Fabino Enterprises Ltd changed from 600 on March 2023 to 0 on March 2022 . This represents a CAGR of -100.00% over 4 yearsThe P/E Ratio of Senores Pharmaceuticals Ltd changed from 45 on March 2025 to 0 on March 2022 . This represents a CAGR of -100.00% over 2 years The Market Cap of Fabino Enterprises Ltd changed from ₹ 6.3 crore on March 2023 to ₹ 0 crore on March 2022 . This represents a CAGR of -100.00% over 4 yearsThe Market Cap of Senores Pharmaceuticals Ltd changed from ₹ 2637 crore on March 2025 to ₹ 0 crore on March 2022 . This represents a CAGR of -100.00% over 2 years The revenue of Fabino Enterprises Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Senores Pharmaceuticals Ltd for the Dec '25 is ₹ 178.34 crore as compare to the Sep '25 revenue of ₹ 167.17 crore. This represent the growth of 6.68% The ebitda of Fabino Enterprises Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Senores Pharmaceuticals Ltd for the Dec '25 is ₹ 57.79 crore as compare to the Sep '25 ebitda of ₹ 54.92 crore. This represent the growth of 5.23% The net profit of Fabino Enterprises Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Senores Pharmaceuticals Ltd changed from ₹ 10.91 crore to ₹ 33.58 crore over 7 quarters. This represents a CAGR of 90.11% The Dividend Payout of Fabino Enterprises Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Senores Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Fabino Enterprises Ltd

Fabino Enterprises Limited is a growing pharmaceutical company promoted by Atul Kumar Jain.
The Company was incorporated as 'Fabino Life Sciences Private Limited' on October 27, 2011 with the Registrar of Companies, Delhi and Haryana.
Subsequently, the Company got converted to Public Limited Company and the name of Company was changed to 'Fabino Life Sciences Limited'.
A fresh Certificate of Incorporation was issued on March 21, 2015 by the Registrar of Companies, Delhi. The Company operate in the business of manufacturing, marketing of pharmaceutical, allopathic, herbal, veterinary, and other consumer products like, packing, trading, etc.
The core business is marketing of pharmaceutical formulation & products in domestic market through its own distribution network and sales force under own brand name, getting Ayurvedic formulations manufactured through loan licensing facilities, packing, labeling etc.

About Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Limited was originally incorporated as 'Senores Pharmaceuticals Private Limited' through a Certificate of Incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.
Thereafter, the name of the Company was changed to 'Senores Pharmaceuticals Limited' upon conversion to a Public Limited Company and a fresh Certificate of Incorporation dated September 4, 2023, was issued by the RoC to the Company. Senores Pharma is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms.
The Regulated Markets business is focused on Regulated Markets of US and Canada.
The Company has adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the mid-market range and received approvals for 19 ANDAs.

FAQs for the comparison of Fabino Enterprises Ltd and Senores Pharmaceuticals Ltd

Which company has a larger market capitalization, Fabino Enterprises Ltd or Senores Pharmaceuticals Ltd?

Market cap of Fabino Enterprises Ltd is 4 Cr while Market cap of Senores Pharmaceuticals Ltd is 4,060 Cr

What are the key factors driving the stock performance of Fabino Enterprises Ltd and Senores Pharmaceuticals Ltd?

The stock performance of Fabino Enterprises Ltd and Senores Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Fabino Enterprises Ltd and Senores Pharmaceuticals Ltd?

As of May 5, 2026, the Fabino Enterprises Ltd stock price is INR ₹20.31. On the other hand, Senores Pharmaceuticals Ltd stock price is INR ₹881.6.

How do dividend payouts of Fabino Enterprises Ltd and Senores Pharmaceuticals Ltd compare?

To compare the dividend payouts of Fabino Enterprises Ltd and Senores Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.